NESS ZIONA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting ...
Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.
Please provide your email address to receive an email when new articles are posted on . In the LOCKCYST I clinical trial, a low dose of Somatuline Depot injection for the treatment of polycystic liver ...
Somatuline Depot (lanreotide) is a brand-name drug prescribed for acromegaly, certain cancers, and carcinoid syndrome in adults. Somatuline Depot is given as a subcutaneous injection by a healthcare ...
The FDA has approved revised labeling to include an extended dosing interval of Somatuline Depot (lanreotide; Ipsen) Injection for the treatment of acromegaly. The updated dosing recommendations allow ...
NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
“For patients who must get regular injections of Somatuline Depot, and the healthcare professionals that administer their medication, this updated design, incorporating Safe’n’Sound® syringe ...
The Food and Drug Administration (FDA) has approved Somatuline Depot (lanreotide; Ipsen Biopharmaceuticals) injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results